Physician profile
Brian P Williams
NPI 1912028622
$19,491.37
in general payments reported to CMS, 2019-2025
40 companies · $4,976 in 2025
The $4,976 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $733 · 2021: $1,010 · 2022: $10K · 2023: $748 · 2024: $862 · 2025: $4,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $2,339 · Travel and Lodging: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $2,339.35 |
| Travel and Lodging | $246.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,864.70 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,135.74 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $720.52 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $644.71 | 2019-2025 | Ofev, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $548.31 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Actelion Pharmaceuticals US, INC. | $251.42 | 2019-2022 | |
| Genzyme Corporation | $179.12 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $176.31 | 2020-2024 | Glassia |
| Pfizer INC. | $174.80 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $165.89 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $158.25 | 2019-2024 | Yupelri |
| Amgen INC. | $148.25 | 2023-2025 | Tezspire |
| Janssen Pharmaceuticals, INC | $130.31 | 2019-2024 | Xarelto |
| Baxter Healthcare | $118.77 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $110.88 | 2021-2025 | Arikayce |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $101.00 | 2021-2022 | |
| Tolmar, INC. | $75.51 | 2023-2025 | Eligard, Jatenzo, Rubraca |
| Abiomed | $75.19 | 2024-2025 | |
| Medivance, INC. | $74.68 | 2021 | |
| Merck Sharp & Dohme LLC | $66.24 | 2019-2020 | |
| Inspire Medical Systems, INC. | $56.90 | 2024-2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $55.85 | 2020-2022 | |
| Electromed, INC. | $52.57 | 2019-2025 | Smartvest |
| Harmony Biosciences LLC | $52.26 | 2022 | |
| Sanofi US Services INC. | $41.46 | 2025 | |
| Inari Medical, INC. | $39.85 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Philips North America LLC | $32.27 | 2021-2022 | |
| Genentech USA, INC. | $29.65 | 2020-2022 | |
| Ambu INC. | $24.52 | 2023 | |
| Sunovion Pharmaceuticals INC. | $23.90 | 2019 | |
| Boston Scientific Corporation | $18.21 | 2023 | Exalt Model D |
| Gilead Sciences, INC. | $17.97 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.31 | 2021 | |
| United Therapeutics Corporation | $17.13 | 2025 | Tyvaso |
| Teva Pharmaceuticals USA, INC. | $17.03 | 2021 | |
| Pharmaand Gmbh | $16.95 | 2025 | Rubraca |
| Convatec INC. | $15.58 | 2024 | |
| Chiesi USA, INC. | $14.76 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.68 | 2021 | |
| Allergan, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.